Efficacy of Oral Tofacitinib in Combination of Narrow Band UVB in Treatment of Vitiligo

Sponsor
Lahore General Hospital
Study ID
NCT07044141
Phase
PHASE1
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Azathioprine — DRUG
    azathioprine 50mg twice daily will be given
  • Tofacitinib — DRUG
    It is a janus kinase inhibitor

Study Details

20 patients will be enrolled. All were given narrowband UVB . 10 wil be give oral azathriopfine . 10 will be given tofacitinib

Key Dates

Start date
Mar 1, 2025
Status verified
May 2025
Primary completion
Sep 30, 2025
Completion
Sep 30, 2025

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Group A
    Azathioprine is an immunomodulator used in treatment of vitiligo
  • Active Comparator: Group B
    Tofacitinib It is a Janu kinase pathway inhibitor

Primary Outcome Measure

VASI improvement upto 50% [ Time Frame: 6 months ]

Related Studies